Pregabalin Capsule
Product Images NDC 80425-0147

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and Placebo. The graph illustrates varying degrees of pain improvement across these doses and placebo.*

FDA Label Image

Figure 10

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR (Loss to Response) over 180 days. Two lines compare Pregabalin and placebo groups, showing a decline over time with the placebo group decreasing more sharply than the Pregabalin group.*

FDA Label Image

Figure 11

A line graph comparing the percent of subjects improved over time from baseline to Week 12 BOCF for Pregabalin versus Placebo. The x-axis shows percent improvement from baseline to Week 12, and the y-axis shows the percent of subjects improved. Pregabalin has a consistently higher percent of subjects improved compared to placebo across the range.*

FDA Label Image

Figure 12

A line chart comparing the percentage of subjects improved over time from baseline to Week 16 BOCF for Pregabalin and Placebo. The x-axis shows percent improved from baseline, while the y-axis indicates the percentage of subjects improved, with distinct lines representing Pregabalin and Placebo groups.*

FDA Label Image

Figure 2

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares Pregabalin 100 mg three times a day to placebo, showing higher patient improvement with Pregabalin across different pain improvement levels.*

FDA Label Image

Figure 3

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. The graph compares data for Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken two times a day, against a placebo group.*

FDA Label Image

Figure 4

A line graph showing the percent of patients improved based on percent improvement in pain from baseline with three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis represents percent of patients improved, while the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 5

A line graph depicting the percent of patients who improved in pain relative to placebo. It compares Pregabalin dosed at 50 mg and 100 mg three times a day against placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis indicates the percent of patients improved.*

FDA Label Image

Figure 6

A bar chart depicting responder rates in two studies, Study E1 and Study E3. The x-axis shows treatment groups including placebo and different dosages of 600 mg/kg/day, while the y-axis shows responder rates as percentages from 0% to 60%. The chart highlights statistically significant differences versus placebo for certain groups.*

FDA Label Image

Figure 7

A line graph showing seizure reduction as median percent change from baseline on the y-axis versus dose in mg/day on the x-axis. Four datasets labeled Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID are illustrated with different markers, all showing dose-dependent seizure reduction trends with significance levels noted for each data point.*

FDA Label Image

Figure 9

A line graph depicting the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. It compares four groups: Pregabalin 600 mg daily dose (solid line), Pregabalin 450 mg daily dose (dotted line), Pregabalin 300 mg daily dose (dashed line), and Placebo (dotted light line). The graph displays patients' pain improvement percentages across a range from 0 to 100%.*

FDA Label Image

Pregabalin 75mg Cap Qty 60 80425 0147

Packaging label for Pregabalin 75 mg capsules, quantity 60, by Advanced Rx Pharmacy of Tennessee, LLC. The label includes the product NDC 80425-0147-02, lot number, expiration date, and storage instructions (store at room temperature 20°-25°C). It also displays barcode and QR code with the labeler's location in Nashville, TN.*

FDA Label Image

Pregabalin 75mg Cap Qty 90 80425 0147

Label for Pregabalin 75 mg capsules, package of 90, by Advanced Rx Pharmacy of Tennessee, LLC. Includes NDC 80425-0147-03, lot number 90PREF51221, and expiration date 11/2022. Storage instructions specify 20°-25°C (68°-77°F). Address is Nashville, TN 37217-2952.*

FDA Label Image

Structure

Chemical structure of pregabalin, showing its molecular composition including amino and carboxyl functional groups with a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.